Business Context and Reporting Period
This Form 8-K filing by GRI Bio, Inc. (GRI) was submitted on November 26, 2025, regarding a notice received from The Nasdaq Stock Market LLC. The company is listed on The Nasdaq Capital Market under the symbol "GRI" and is classified as an Emerging Growth Company.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It references the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as the source of data indicating non-compliance with the minimum stockholders' equity requirement.
Material Changes and Listing Status
On November 26, 2025, GRI Bio received a notice from Nasdaq stating it is not in compliance with Listing Rule 5550(b)(1) due to insufficient stockholders' equity. The rule requires companies with a market value of listed securities under $35,000,000 and annual net income under $500,000 to maintain stockholders' equity of at least $2,500,000. The filing indicates the company failed to meet this threshold based on its September 30, 2025, financials.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The company has 45 calendar days, until January 10, 2026, to submit a Compliance Plan to regain compliance.
- Extension Possibility: If the Compliance Plan is accepted, Nasdaq may grant an additional 180-day extension to achieve the required equity level.
- Risks: There is no assurance the Compliance Plan will be accepted or that the company will regain compliance. If the plan is rejected, the stock is subject to delisting, though the company retains the right to appeal to a Nasdaq Hearing Panel.
- Current Status: The notice has no immediate effect on the company's continued listing, provided other listing requirements are met.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the quarter ended September 30, 2025.
- Confirm the company's current market value of listed securities and annual net income to validate the applicable Nasdaq rule tier.
- Monitor the submission of the Compliance Plan by the January 10, 2026 deadline.
- Review any subsequent announcements regarding the acceptance or rejection of the Compliance Plan by Nasdaq.